Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

OBJECTIVE: To investigate the risk of developing lower intestinal perforations (LIPs) in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ). METHODS: In 13 310 patients with RA observed in the German biologics register Rheumatoid Arthritis: Observation of Biologic Therapy, 141 se...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Rheum Dis
Auteurs principaux: Strangfeld, A, Richter, A, Siegmund, B, Herzer, P, Rockwitz, K, Demary, W, Aringer, M, Meißner, Y, Zink, A, Listing, J
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2017
Sujets:
Clinical and Epidemiological Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5445993/
https://ncbi.nlm.nih.gov/pubmed/27405509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-209773
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires